Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

The stock's fall snapped a four-day winning streak.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

See the latest Merck & Co Inc stock price (MRK:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Review the current Merck & Co Inc (MRK:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MRK is the best investment for you.

According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 3.74%, which means ...

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.